Re­gen­eron, Sanofi show re­straint on Dupix­ent price hike, but Pfiz­er’s hard charge con­tin­ues to spur calls for a rad­i­cal change-up

BIOREG­NUM — the view from John Car­roll

With the price of drugs front and cen­ter in Wash­ing­ton DC these days, Re­gen­eron and Sanofi are at­tract­ing ku­dos for their de­ci­sion to hold back the price hike on Dupix­ent to a mere 3%, which the phar­ma gi­ant notes is well with­in the rate of med­ical in­fla­tion — their cap on price in­creas­es.

Both of these com­pa­nies went through the ringer on PC­SK9 pric­ing — which have come down — and Re­gen­eron CEO Len Schleifer has been a con­sis­tent coun­sel for avoid­ing the big an­nu­al price in­creas­es that is at­tract­ing so much crit­i­cism these days.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE